Junshi Biosciences Submits IPO Prospectus Featuring GC203, the World’s First Non-Viral Vector-Engineered TIL Therapy Granted Clinical Approval

GC203 relies on the company's independently developed, globally leading DeepTIL.^®Cell Enrichment and Expansion with NovaGMP^®Developed through a gene modification technology platform.Non-viral vector-mediatedThe gene engineering technology enables natural TIL cellsStably Expressing Membrane-Bound, Spontaneously Aggregating Cytokine IL-7. It has previously won the highest award in the "National Disruptive Technology Innovation Competition" organized by the Ministry of Science and Technology, and has been included in the Disruptive Technology Reserve.

GC203 TargetingFailure of Multiple Lines of TreatmentGynecological tumor patients exhibit excellent safety and clinical efficacy. During the treatment process, all patientsNo need for high-dose chemotherapy conditioning, no need for IL-2 combination, general wardComplete the treatment，And no serious adverse events occurred.

Patients with platinum-resistant ovarian cancerIt can also produce a high proportion of objective remission efficacy,All cervical cancer patients enrolled in the study experienced varying degrees of tumor shrinkage.3 casesPatientThe tumor was completely cleared., ObtainCREfficacy.

A single-arm, multi-center, open-label Phase I clinical trial evaluating the safety and efficacy of GC203 in treating advanced solid tumors will be conducted byFudan University Shanghai Cancer CenterAs the leading organization,Professor Xiaohua WuAndProfessor Wang HongxiaAs the principal investigator, I am currently recruiting participants from the public.

If you would like to learn more about this clinical trial, please consult through the following contact information.

Teacher Zhang：18019732895   

Teacher Cheng: 18001759113

Juncell Therapeutics is committed to developing high-quality, highly accessible TIL cell therapies for a wide range of advanced solid tumor types. As a national high-tech enterprise and a specialized and innovative small and medium-sized enterprise in Shanghai, the company has independently established the internationally leading DeepTIL platform.^®Cell Enrichment Amplification and NovaGMP^®Gene Modification Technology Platform: A Disruptive Solution to Key Common Issues in TIL Therapy, Achieving Multi-Level Goals for TIL Cells to Be "Cultivable, Well-Cultured, Affordable, and Easy-to-Use."

Juncell Therapeutics has 2 innovative TIL therapies entering the clinical trial stage in China.9 TypesExcellent clinical efficacy has been demonstrated in various types of advanced solid tumors (includingPancreatic Cancer and High-Grade Glioma Failed by Multiple Lines of Treatment), among which7 casesThe patient's tumor wasComplete Clearance，The longest tumor-free survival time has been nearly 3 years.。